Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant and 1 in 8 deaths beyond a year are due to CAV. Abnormal vascular fibroproliferation in CAV occurs as a result of coronary endothelial inflammation, injury, and dysfunction trig- M ore than 5,000 heart transplants are performed annually worldwide, improving the survival of patients with advanced heart disease (1). Cardiac allograft vasculopathy (CAV) has been a major impediment to successful long-term outcomes in heart transplantation. Registry data show a high incidence of CAV and minimal reduction over the past 2 decades, from 32% to 29% and 46% to 40% at 5 and 8 years post-transplant, respectively (1). Over the same period, 5-year survival 
for CAV detected within 3 years of transplant has improved marginally, from 71% to 76%, but remains lower than the 82% survival for patients without CAV (1) . Notably, CAV is a leading cause of longterm mortality, accounting for up to 1 in 8 deaths beyond a year post-transplant (1) . Evolving definitions for CAV ( Table 1 ) and changing trends in clinical practice, including the use of statins and mammalian target of rapamycin inhibitors (mTORi), have modified the natural history of disease (2) . 
NONIMMUNE FACTORS
Nonimmune insults predisposing to CAV include vascular risk factors (in both donors and recipients of older age, male sex, obesity, hyperglycemia, hyperlipidemia), ischemic heart disease etiology, brain death, organ preservation, and ischemia-reperfusion injury. These share in common inflammatory injury causing endothelial dysfunction. Cytomegalovirus (CMV) infection is associated with the development of CAV (9) . CMV generates a proatherogenic milieu through production of inflammatory cytokines, expression of adhesion molecules, mononuclear activation, and smooth muscle cell proliferation (10) .
CMV also impairs endothelial nitric oxide synthasemediated coronary vasodilatation through increased production of the nitric oxide synthase inhibitor asymmetric dimethylarginine (11) . There is also evidence for CMV molecular mimicry of endothelial cell surface molecules and subsequent immune-mediated endothelial injury (12) . (19, 20) . In the largest series (N ¼ 110), SPECT had 63% to 84% sensitivity and 70% to 78% specificity for detecting minor to severe ($50% stenosis) CAV (20) .
Positron emission tomography (PET) MPI has superior diagnostic accuracy to SPECT for evaluation of coronary artery disease (21) . The prognostic value of PET perfusion and flow quantification is also well demonstrated (22, 23) . Flow quantification using PET holds the most potential for early CAV diagnosis by detecting homogenous reductions in flow that may occur with diffuse disease. This is in contrast to modalities that identify disease on the basis of heterogeneity in perfusion (or contractility), which rely on differences relative to a zone presumed to be normal.
Such techniques define only the territory supplied by the most severe stenosis, which underestimates disease if it is diffuse with no normal reference region.
Hence, flow quantification is better able to detect microvascular or diffuse disease (22) . Small studies of 19 to 27 patients have shown moderate inverse correlation between PET flow reserve and IVUS indexes of CAV (24, 25) . Prognostic value was also reported in a retrospective study (N ¼ 140) for PET parameters, including reduced stress myocardial blood flow and flow reserve (26) . Prospective studies are needed. A "primary vessel" denotes the proximal and middle third of the left anterior descending artery, left circumflex, the ramus, and the dominant or codominant right coronary artery. A "secondary branch vessel" includes the distal third of the primary vessels or any segment within a large septal perforator, diagonals, and obtuse marginal branch or nondominant right coronary artery.
Restrictive cardiac allograft physiology is defined as symptomatic heart failure with echocardiographic E/A velocity ratio >2, isovolumetric relaxation time <60 ms, deceleration time <150 ms, or restrictive hemodynamics (right atrial pressure >12 mm Hg, pulmonary capillary wedge pressure >25 mm Hg, cardiac index <2 l/min/m 2 ). Reprinted with permission from Mehra et al. (2) . Immune and nonimmune factors cause endothelial inflammation and injury, triggering vascular fibroproliferation of the coronary vasculature and allograft dysfunction. Grade $2R rejection was increased with the CNI-free approach ( Table 3 ). The effect of mTORi on CAV has also been examined in maintenance heart transplant patients. 
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